Liminatus Pharma Faces Nasdaq Delisting

Liminatus Pharma gets Nasdaq delisting notice after failing to meet market value requirements. Stock down 95.5%.

2026-05-22 00:42|Last updated: 2026-05-22 00:45

Liminatus Pharma Faces Nasdaq Delisting — Photo: Prepared by Bond.az

Liminatus Pharma (NASDAQ:LIMN) received a delisting notice from Nasdaq on Tuesday. The company failed to meet the $50 million market value of listed securities and $15 million market value of publicly held shares requirement by May 18, 2026.

With a current market cap of just $10.91 million, the stock has plunged 95.5% over the past year, trading at $0.25. Bond.az data shows the company is burning cash quickly, with negative free cash flow of $9.98 million.

Unless Liminatus appeals to the Nasdaq Hearings Panel by May 27, 2026, trading will be suspended on May 29, 2026. The company intends to appeal.

More News

Amber International shareholder to distribute stake pro rata

2026-06-01 12:34

401

Amber International shareholder to distribute stake pro rata

Amber International's principal shareholder distributes all Class A shares pro rata to existing shareholders; market impact and financial highlights.

COMPANY →

Palladyne AI Adds Two Retired Generals to Board

2026-06-01 12:33

213

Palladyne AI Adds Two Retired Generals to Board

Palladyne AI appoints two retired generals to its defense advisory board. Stock up 98% YTD.

COMPANY →

Cellectar Plans Phase 3 Trial for WM After BTKi

2026-06-01 12:32

381

Cellectar Plans Phase 3 Trial for WM After BTKi

Cellectar Biosciences reports promising Phase 2 results for iopofosine I 131 in Waldenström macroglobulinemia after BTKi therapy, plans Phase 3 trial.

COMPANY →

2026-06-01 11:33

363

essensys Shareholders Approve Re-Registration as Private Company

essensys shareholders approve re-registration as a private company after AIM delisting. All voting shareholders backed the resolution.

COMPANY →

Causeway Capital Boosts Melrose Stake to 5.12%

2026-06-01 08:31

890

Causeway Capital Boosts Melrose Stake to 5.12%

Causeway Capital increased its stake in Melrose Industries to 5.12%. The investment firm now holds over 63 million voting rights.

COMPANY →

2026-06-01 08:03

968

Ignitis grupė starts search for new CEO

Ignitis grupė launches CEO search in Lithuania. Learn about requirements and application deadline for the new CEO position.

COMPANY →

Aquila Renewables: Adviser Withholds Fee Data

2026-06-01 07:33

417

Aquila Renewables: Adviser Withholds Fee Data

Aquila European Renewables says its investment adviser Aquila Capital has not provided complete fee information. The Board is considering legal action.

COMPANY →

USA Rare Earth Plans €175M France Investment

2026-06-01 07:31

226

USA Rare Earth Plans €175M France Investment

USA Rare Earth reveals €175 million investment plan in France for metal, alloy and magnet manufacturing, aiming to create over 300 jobs by 2030.

COMPANY →

2026-06-01 07:30

762

Lucid Group Names Silvio Napoli CEO

Lucid Group appoints Silvio Napoli as CEO effective immediately. Stock up 12% in past week but down 38% YTD. Company faces financial challenges.

COMPANY →

Mkango Reports Q1 2026 Financial Results

2026-06-01 07:04

680

Mkango Reports Q1 2026 Financial Results

Mkango Resources reports Q1 2026 financial results. Details on rare earth projects, recycling operations, and SPAC merger.

COMPANY →

Greatland secures $500m debt facility, OKs Havieron

2026-06-01 07:02

274

Greatland secures $500m debt facility, OKs Havieron

Greatland Resources secures $500 million corporate debt facility and board approval for Havieron gold-copper project final investment decision.

COMPANY →

2026-06-01 07:00

543

Calnex director buys shares at 69.9p

Calnex Solutions non-executive director Graeme Bissett buys 28,610 shares at 69.9p each on the London Stock Exchange.

COMPANY →

...